lifestyle.projectdiaspora.org

Author: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Grants of Inducement Awards

May 6, 2026
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million

May 4, 2026
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock

May 4, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

May 4, 2026
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

May 3, 2026
Spyre Therapeutics Announces Grants of Inducement Awards

May 3, 2026
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026

April 30, 2026
Spyre Therapeutics Announces Grants of Inducement Awards

April 29, 2026
Spyre Therapeutics to Participate in Upcoming March Investor Conferences

February 24, 2026
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 19, 2026